AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23773637 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (monthly pulse-cyclophosphamide + azathioprine + prednisolone)
Number of subjects: 3
Study 23774433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (adolescents)
Number of subjects: 0
Study 23774433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 15 mg/kg (children aged 2 to 12 years)
Number of subjects: 0
Study 23774433 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 15 mg/kg (children 2 to 12 years)
Number of subjects: 0
Study 23775962 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg once per day or 400 mg twice per day if no initial response
Number of subjects: 25
Study 23777553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSAHS
Number of subjects: 108
Study 23777553 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 23777764 — intervention group
Group type: EXPERIMENTAL
Intervention: MDASI-CML administered to patients every 2 weeks for 1 year
Number of subjects: 152
Study 23778184 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical frequency domain imaging (OFDI)
Number of subjects: 97
Study 23778184 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention on identified FS)
Number of subjects: 97
Study 23778400 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Number of subjects: 67
Study 23778400 — intervention group
Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 67
Study 23778831 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 0
Study 23780842 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution microendoscopy (HRME) by expert microendoscopists
Number of subjects: 68
Study 23780842 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution microendoscopy (HRME) by novice microendoscopists
Number of subjects: 68
Study 23780842 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HRME performance
Number of subjects: 68
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV 300/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Number of subjects: 40
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV 400/100 mg once daily with zidovudine/lamivudine 300/150 mg twice daily
Number of subjects: 40
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV treatment
Number of subjects: 40
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal UGT1A1 genotype
Number of subjects: 40
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal UGT1A1 genotype or cord blood ATV concentration
Number of subjects: 40
Study 23782005 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/RTV treatment of mothers
Number of subjects: 40
Study 23782158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Number of subjects: 85
Study 23782158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg
Number of subjects: 85
Study 23782158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 85
Study 23782157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, 560 mg daily
Number of subjects: 111
Study 23782492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal continuous positive airway pressure (CPAP) treatment
Number of subjects: 44
Study 23782511 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MSCs therapy (5 × 10(7) cells injected twice through the hepatic artery at weeks 4 and 8)
Number of subjects: 12
Study 23782511 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MSCs therapy
Number of subjects: 12
Study 23782682 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical peripheral blood stem cell infusions (1-2x10^8 CD3+ cells/kilogram)
Number of subjects: 25
Study 23782682 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for cytokine release syndrome (CRS)
Number of subjects: 25
Study 23782711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone (25 mg/day, adjusted for renal function)
Number of subjects: 199
Study 23783429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly-generated trivirus-directed T cells
Number of subjects: 12
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 14343
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 14343
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 14343
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 14343
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 14343
Study 23784912 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (categorical analysis)
Number of subjects: 14343
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT parameters
Number of subjects: 87
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of SUV(max)
Number of subjects: 87
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum SUV(max)
Number of subjects: 87
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Average SUV(max)
Number of subjects: 87
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of SUV(max) (quartile analysis)
Number of subjects: 87
Study 23785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of SUV(max) (multivariable analysis)
Number of subjects: 87
Study 23786166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 5279
Study 23786166 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 5279
Study 23786166 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime and Metronidazole (combined)
Number of subjects: 5279
Study 23786166 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 5279
Study 23786513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk-taking
Number of subjects: 245
Study 23786513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity with multiple partners
Number of subjects: 245
Study 23786513 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological testing for STI+
Number of subjects: 245
Study 23786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments including 6-minute walk test and 3-minute stair climb test
Number of subjects: 43
Study 23786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum and urinary oligosaccharide levels analysis
Number of subjects: 43
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) in female patients (0.83 ± 0.09)
Number of subjects: 700
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference vessel area in female patients (11.4 ± 3.3 mm²)
Number of subjects: 700
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel area in female patients (9.0 ± 3.3 mm²)
Number of subjects: 700
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque burden in female patients (69.8 ± 13.7%)
Number of subjects: 700
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value of angiography in female patients (44%)
Number of subjects: 700
Study 23787231 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-MLA concordance rate in female patients (64%)
Number of subjects: 700
Study 23787357 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/US-fusion-guided biopsy
Number of subjects: 582
Study 23787357 — intervention group
Group type: COMPARATOR
Intervention: 12-core biopsy
Number of subjects: 582
Study 23787555 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone 1 mg/kg daily, max 60 mg/day) until complete remission, followed by gradual dosage reduction.
Number of subjects: 27
Study 23787555 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone)
Number of subjects: 27
Study 23788609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement and systemic antibiotics
Number of subjects: 59
Study 23790554 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Burden of Illness index for Depression (IBI-D)
Number of subjects: 956
Study 23790772 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant whole-pelvis radiation therapy (RT)
Number of subjects: 12
Study 23790798 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine treatment in RAEB-t group (n = 26)
Number of subjects: 183
Study 23790798 — intervention group
Group type: COMPARATOR
Intervention: Decitabine treatment in MDS group (n = 157)
Number of subjects: 183
Study 23791392 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 525797 (250, 500, 1000, or 1500 mg every 2 weeks)
Number of subjects: 26
Study 23791392 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 525797 (500 mg cohort)
Number of subjects: 26
Study 23791541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² on day 1 and bortezomib 1.3 mg/m² on days 1, 4, 8, 11 every 3 weeks
Number of subjects: 82
Study 23791541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and bortezomib
Number of subjects: 82
Study 23792193 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA/CTP
Number of subjects: 91
Study 23792193 — intervention group
Group type: COMPARATOR
Intervention: CTA
Number of subjects: 91
Study 23793683 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 720
Study 23793683 — intervention group
Group type: COMPARATOR
Intervention: Nutrition intervention (control)
Number of subjects: 720
Study 23793683 — intervention group
Group type: COMPARATOR
Intervention: HCT-only control
Number of subjects: 720
Study 23793872 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 35
Study 23793872 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 35
Study 23794578 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly WelTel SMS 'check-in'
Number of subjects: 686
Study 23794578 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 686
Study 23794582 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A)
Number of subjects: 456
Study 23795577 — intervention group
Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg (single dose on day 1)
Number of subjects: 24
Study 23795577 — intervention group
Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg (multiple doses, once daily for 14 days)
Number of subjects: 24
Study 23795577 — intervention group
Group type: EXPERIMENTAL
Intervention: LDMP 7.5 mg
Number of subjects: 24
Study 23795661 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group A)
Number of subjects: 71
Study 23795661 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 48 weeks (Group B)
Number of subjects: 71
Study 23795661 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-IFNα-2a 180 μg per week and ribavirin 1000/1200 mg daily for 24 weeks (Group C)
Number of subjects: 71
Study 23795661 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA below 1000 IU/mL by day 6
Number of subjects: 71
Study 23795661 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable HCV RNA at week 12
Number of subjects: 71
Study 23795975 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/day
Number of subjects: 0
Study 23795975 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 0
Study 23795975 — intervention group
Group type: COMPARATOR
Intervention: Comparator (glyburide, thiazolidinedione, or metformin)
Number of subjects: 0
Study 23796131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention promoting weight loss through decreased caloric intake and increased physical activity
Number of subjects: 5145
Study 23796131 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (control group)
Number of subjects: 5145
Study 23796526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural modification and risk factor treatment
Number of subjects: 563
Study 23796921 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23799873 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus added to standard therapy of Rituximab and DHAP
Number of subjects: 0
Study 23799875 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD-BPRS11 rating scale
Number of subjects: 0
Study 23799875 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-D6 rating scale
Number of subjects: 0
Study 23799875 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Scale
Number of subjects: 0
Study 23799932 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-ELT (cataract surgery combined with excimer laser trabeculotomy)
Number of subjects: 64
Study 23799943 — intervention group
Group type: EXPERIMENTAL
Intervention: MOHR assessment and subsequent counseling and support
Number of subjects: 9
Study 23800144 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment approach for chronic pain
Number of subjects: 409
Study 23800355 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of one or more of 11 best practices for medication reconciliation
Number of subjects: 6
Study 23800355 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data collection on unintentional medication discrepancies
Number of subjects: 6
Study 23800355 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data collection on history and reconciliation errors
Number of subjects: 6
Study 23800418 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (STAR*D)
Number of subjects: 2093
Study 23800418 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic setting (Italian sample)
Number of subjects: 2093
Study 23800455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated and branched endovascular aortic repair (FEVAR)
Number of subjects: 30
Study 23800455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23800488 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher discounting rates
Number of subjects: 30
Study 23800488 — intervention group
Group type: COMPARATOR
Intervention: Executive attention control network
Number of subjects: 30
Study 23800556 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23801020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1197
Study 23801020 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator-only therapy
Number of subjects: 1197
Study 23801633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 60
Study 23801798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) in closed-loop mode for 28 hours
Number of subjects: 20
Study 23801798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) in open-loop mode for 14 hours
Number of subjects: 20
Study 23801798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) overall system functionality
Number of subjects: 20
Study 23803225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) and low-dose interferon-α2a (3 MIU thrice weekly)
Number of subjects: 146
Study 23803225 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus interferon-α2a (9 MIU) from AVOREN study
Number of subjects: 146
Study 23803880 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 servings of fruit and vegetables per day
Number of subjects: 71706
Study 23803880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 fruit per day
Number of subjects: 71706
Study 23803880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 vegetables per day
Number of subjects: 71706
Study 23804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia added to multivariable clinical risk model
Number of subjects: 815
Study 23804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia
Number of subjects: 815
Study 23804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia in patients with previous coronary artery disease
Number of subjects: 815
Study 23804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical net reclassification index
Number of subjects: 815
Study 23804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous net reclassification improvement
Number of subjects: 815
Study 23805209 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 infection
Number of subjects: 13735
Study 23805209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime sexual partners
Number of subjects: 13735
Study 23805209 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 partners in the past year
Number of subjects: 13735
Study 23805209 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 new partners in the past year
Number of subjects: 13735
Study 23805209 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent partners in the past year
Number of subjects: 13735
Study 23805387 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.008% indigocarmine added to the water method
Number of subjects: 168
Study 23805387 — intervention group
Group type: COMPARATOR
Intervention: Water method (control)
Number of subjects: 168
Study 23805395 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water infusion colonoscopy
Number of subjects: 3
Study 23805395 — intervention group
Group type: COMPARATOR
Intervention: Conventional air insufflation colonoscopy
Number of subjects: 3
Study 23806958 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-coated polypropylene mesh
Number of subjects: 207
Study 23808960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 528
Study 23809138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg
Number of subjects: 0
Study 23809138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23809203 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (FH) of aortic aneurysms
Number of subjects: 426
Study 23809536 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 498
Study 23809536 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 498
Study 23809536 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D and DBP
Number of subjects: 498
Study 23809766 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily in cycles of 3 weeks on/1 week off treatment until disease progression, unacceptable toxicity, death or patient/physician decision to discontinue.
Number of subjects: 36
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrub Nurse
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic Technologist (RT)
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Field Size Decrease
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Angulation of C-arm
Number of subjects: 39
Study 23810300 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Subtraction Acquisitions
Number of subjects: 39
Study 23810467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg daily and olaparib 200 mg BID
Number of subjects: 28
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg/day
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 30 mg/day
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 60 mg/day
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 400 mg/day
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (various doses)
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (doses >80 mg/day)
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (doses >60 mg/day)
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib in BRCA1 or BRCA2 mutation carriers with ovarian cancer
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib in BRCA1 or BRCA2 mutation carriers with breast cancer
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer
Number of subjects: 100
Study 23810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 100
Study 23810884 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-erosion
Number of subjects: 126
Study 23810884 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-CN
Number of subjects: 126
Study 23812930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg/day on days 1-14) in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Number of subjects: 21
Study 23812930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg/day)
Number of subjects: 21
Study 23812932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenous every 21 days)
Number of subjects: 11
Study 23813557 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoxyl sulfate
Number of subjects: 203
Study 23813557 — intervention group
Group type: EXPERIMENTAL
Intervention: p-Cresyl sulfate
Number of subjects: 203
Study 23813757 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin intrinsic fluorescence (SIF)
Number of subjects: 1185